3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
3
Osteosarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Hodgkin Disease
1
Hepatoblastoma
1
Hemangiosarcoma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
Cyclophosphamide
4
Topotecan
3
Ifosfamide
3
Doxorubicin
3
seclidemstat
2
pazopanib
2
Biopsy
2
tebentafusp
1
selinexor
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
fludarabine phosphate
1
fludarabine
1
dostarlimab
1
devimistat
1
cobimetinib
1
cabozantinib
1
atezolizumab
1
Zoledronic Acid
1
X-Rays
1
Vemurafenib
1
Sunitinib
1
Specimen Handling
1
Sirolimus
1
Simvastatin
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Radiation
1
Proton Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Clear Cell
×
dostarlimab
×
Sarcoma
×
Clear all
NCT04274023
2024-02-01
ACCeSs
Italian Sarcoma Group
Phase 2
Terminated
3 enrolled